Pharvaris (PHVS)
(Delayed Data from NSDQ)
$21.25 USD
-0.04 (-0.19%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $21.07 -0.18 (-0.85%) 5:02 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHVS 21.25 -0.04(-0.19%)
Will PHVS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PHVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHVS
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
PHVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know
Other News for PHVS
Bullish Two Hundred Day Moving Average Cross - PHVS
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials
Pharvaris files for automatic mixed securities shelf
Pharvaris files automatic mixed securities shelf